Helix BioPharma set to receive up to C$10M in funding from institutional investor Lind Partners
Each convertible security issued by Helix will have a two-year term with an interest rate of 8.75% per annum
Company
Helix BioPharma Corp.
TSE:HBP
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer-based on its proprietary technologies - DOS47. It is a naturally occurring enzyme that converts urea into ammonia and generates an alkaline media at the site of action. This effectively combats the acidic tumor microenvironment that is known to suppresses the immune system. Helix’s product development initiatives include its lead candidate L-DOS47 which is currently in clinical studies for lung and pancreatic cancer.
39 stories · page 2 of 2
Helix BioPharma ends fiscal 2Q with C$4.1M in cash after successfully divesting Polish subsidiary
In December, Ontario-based Helix disposed its remaining interest in its Polish subsidiary for gross proceeds of $2,308,000
Helix BioPharma announces the appointment of Dr Frank Gary Renshaw to its Scientific Advisory Board
Dr Renshaw is a healthcare industry executive and Oncologist-Hematologist drug developer with several decades of oncology drug development experience
Helix BioPharma closes divesture of Polish subsidiary
Helix signed a definitive agreement with CAIAC to purchase Helix's remaining holdings in the subsidiary Helix Immuno-Oncology S.A
Archive
FTSE 100 closes higher as traders focus on EU talks; Wall Street finds its way to positive territory
London's leading index jumped 42 points to 6,495 Wednesday
Archive
NA Proactive news snapshot: FansUnite Entertainment, First Cobalt, Newrange Gold, Innocan Pharma, Great Panther Mining UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Helix BioPharma announces reduced loss and R&D spend in fiscal first quarter
For the three months, the company reported a net loss of C$222,000, reduced from a loss of C$2.21 million in the same period in 2019
Helix BioPharma says to close planned divestment of remaining shares in Polish subsidiary, Helix Immuno-Oncology SA on September 30
The transaction was scheduled to close on August 31, but that date has now been moved to September 30
Helix BioPharma set to build on early successes as it extends immunotherapy collaboration with Moffitt cancer center
Helix and Moffitt have already developed a new pancreatic adenocarcinoma mouse model suitable for testing Helix's lead clinical compound L-DOS47
NA Proactive news snapshot: American Battery Metals, mCloud Technologies, Harvest One Cannabis, Exro Technologies, BetterLife Pharma, Ideanomics UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Helix BioPharma to divest its remaining shares in Polish subsidiary Helix Immuno-Oncology
The Toronto-based immuno-oncology company owns 51% of the issued and outstanding shares of the subsidiary
Helix BioPharma announces data from L-DOS47 dose escalation study of non-small cell lung cancer patients
The company said L-DOS4, in combination with pemetrexed and carboplatin, appeared to be well tolerated with promising anti-tumor activity
Helix BioPharma maintaining business continuity amid coronavirus pandemic
The Toronto-based company continues to engage investment bankers and is preparing for a capital raise in combination with an up-listing to the Nasdaq
Noble reiterates Outperform rating on Helix BioPharma following in-line 2Q results
Noble noted Helix BioPharma has a cash position of $16 million this year
Helix BioPharma Corp seeing good progress in clinical trials of cancer-fighting drug
Patient enrollment and screening commenced on the LDOS006 Phase Ib/II clinical study in the US for the treatment of patients with previously treated advanced pancreatic cancer
Helix BioPharma closes C$6 million private placement
It intends to use the proceeds of the private placement for working capital and research and development activities
Noble initiates coverage on Helix BioPharma with an Outperform rating
Noble set a C$2.50 price target on the stock while hailing encouraging results from the ongoing human clinical trials of cancer-fighting drug
Helix Biopharma shares rise despite posting $1.9 million loss in fiscal 2Q
The company is spending $1.3 million on research and development for its innovative cancer therapy
Helix Biopharma starts enrolling next cohort in Poland
Helix BioPharma (TSE:HBP),which is developing candidates for preventing and treating cancer, has started enrolling the next cohort under its phase I/II clinical study.